GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sernova Biotherapeutics Inc (TSX:SVA) » Definitions » Shares Outstanding (EOP)

Sernova Biotherapeutics (TSX:SVA) Shares Outstanding (EOP) : 328.49 Mil (As of Jan. 2025)


View and export this data going back to 1998. Start your Free Trial

What is Sernova Biotherapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Sernova Biotherapeutics's shares outstanding for the quarter that ended in Jan. 2025 was 328.49 Mil.

Sernova Biotherapeutics's quarterly shares outstanding increased from Oct. 2024 (325.33 Mil) to Jan. 2025 (328.49 Mil). It means Sernova Biotherapeutics issued new shares from Oct. 2024 to Jan. 2025 .

Sernova Biotherapeutics's annual shares outstanding increased from Oct. 2023 (303.33 Mil) to Oct. 2024 (325.33 Mil). It means Sernova Biotherapeutics issued new shares from Oct. 2023 to Oct. 2024 .


Sernova Biotherapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for Sernova Biotherapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sernova Biotherapeutics Shares Outstanding (EOP) Chart

Sernova Biotherapeutics Annual Data
Trend Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.26 261.13 303.33 303.33 325.33

Sernova Biotherapeutics Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.33 303.41 303.61 325.33 328.49

Competitive Comparison of Sernova Biotherapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, Sernova Biotherapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sernova Biotherapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sernova Biotherapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Sernova Biotherapeutics's Shares Outstanding (EOP) falls into.


;
;

Sernova Biotherapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Sernova Biotherapeutics  (TSX:SVA) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Sernova Biotherapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Sernova Biotherapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Sernova Biotherapeutics Business Description

Traded in Other Exchanges
Address
700 Collip Circle, Suite 114, London, ON, CAN, N6G 4X8
Sernova Biotherapeutics Inc is a clinical-stage company developing regenerative medicines. The company develops Cell Pouch with human donor cells or stem cells to create a biohybrid organ. The Cell Pouch is a implantable medical device designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells, which then release proteins, hormones, or other factors into the bloodstream for the long-term treatment of multiple chronic diseases such as type 1 diabetes, hypothyroid disease, and rare diseases such as hemophilia A.
Executives
Steven Sangha Director
Brett Alexander Whalen Director
Jeffrey Bacha Director

Sernova Biotherapeutics Headlines

From GuruFocus

SINOVAC Varicella Vaccine Prequalified by WHO

By Business Wire Business Wire 11-04-2022